AASLD Educating and Engaging in the Digital Age
Neeral L. Shah, Jennifer B. Miller, Richard S. Kalman, Sonal Kumar – 11 July 2021
Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP‐Based Therapy
Michel Bazinet, Mark Anderson, Victor Pântea, Gheorghe Placinta, Iurie Moscalu, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Liviu Iarovoi, Valentina Smesnoi, Tatina Musteata, Alina Jucov, Ulf Dittmer, Jeff Gersch, Vera Holzmayer, Mary Kuhns, Gavin Cloherty, Andrew Vaillant – 9 July 2021 – Therapy with nucleic acid polymers (NAPs), tenofovir disoproxil fumarate (TDF), and pegylated interferon (pegIFN) achieve high rates of HBsAg loss/seroconversion and functional cure in chronic hepatitis B virus (HBV) infection.
Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next?
Mercedes Iñarrairaegui, Bruno Sangro – 9 July 2021
Letter to the Editor: Is Aspirin a Drug or Just a Marker for Biliary Cancer?
Jun‐Wei Zhang, Xu Yang, Hui‐Ru Ding, Lei Zhang, Yi‐Yao Xu, Xin‐Ting Sang, Hai‐Tao Zhao, Wei‐Guang Zhang, Xin Lu – 8 July 2021
Issue Information
8 July 2021
Issue Information
8 July 2021
Issue Information
8 July 2021
Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data
James M. Paik, Seema Mir, Saleh A. Alqahtani, Youssef Younossi, Janus P. Ong, Zobair M. Younossi – 7 July 2021 – Nonalcoholic fatty liver disease (NAFLD) is a common but complex chronic liver disease, driven by environmental and genetic factors. We assessed metabolic and dietary risk factor associations with NAFLD liver mortality using the Global Burden of Disease (GBD) 2017 data. NAFLD liver deaths were calculated (per 100,000) as age‐standardized rates (ASRs) from 195 countries and territories (21 GBD regions; 7 GBD superregions).